News

Pharmabiz1d
Johnson & Johnson announces new data from Tremfya phase 3 QUASAR LTE study in adults with moderately-to-severely active ulcerative colitis
Johnson & Johnson announces new data from Tremfya phase 3 QUASAR LTE study in adults with moderately-to-severely active ulcerative colitis: San Diego, California Tuesday, May 6, 2 ...
Hidradenitis Suppurativa Market Analysis And Forecast, 2025-2035 - Emerging Biotech Innovations Offer New Hope For Hidradenitis Suppurativa Patients
The "Hidradenitis Suppurativa Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's ...
European Medical Journal2d
Guselkumab Shows Long-Term Efficacy in Ulcerative Colitis Treatment
Guselkumab significantly improves clinical remission rates in patients with active ulcerative colitis, according to phase 3 data.
Applied Clinical Trials Online2d
QUASAR LTE Trial Shows Tremfya Produces Sustained Clinical, Endoscopic Remission Through 92 Weeks in Ulcerative Colitis
New long-term extension data from the Phase IIb/III QUASAR trial demonstrate that Tremfya (guselkumab) maintains durable ...
TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years
Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC ...